KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Flynn, 2017, Clinical practice guideline for screening and management of high blood pressure in children and adolescents, Pediatrics, 140, 10.1542/peds.2017-1904
Muntner, 2019, Measurement of blood pressure in humans: a scientific statement From the American Heart Association, Hypertension, 73, e35, 10.1161/HYP.0000000000000087
Turner, 2007, Sphygmomanometer calibration--why, how and how often?, Aust Fam Physician, 36, 834
Agarwal, 2016, Masked uncontrolled hypertension in CKD, J Am Soc Nephrol, 27, 924, 10.1681/ASN.2015030243
Ahmad, 2017, Validity of cardiovascular data from electronic sources: the multi-ethnic study of atherosclerosis and HealthLNK, Circulation, 136, 1207, 10.1161/CIRCULATIONAHA.117.027436
Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, 1376, 10.1016/j.jacc.2019.03.009
Williams, 2018, 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, J Hypertens, 36, 1953, 10.1097/HJH.0000000000001940
Kallioinen, 2017, Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review, J Hypertens, 35, 421, 10.1097/HJH.0000000000001197
Drawz, 2018, BP Measurement in clinical practice: time to SPRINT to guideline-recommended protocols, J Am Soc Nephrol, 29, 383, 10.1681/ASN.2017070753
Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317
de Galan, 2009, Lowering blood pressure reduces renal events in type 2 diabetes, J Am Soc Nephrol, 20, 883, 10.1681/ASN.2008070667
Peralta, 2016, Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of Small Subcortical Strokes (SPS3) Randomized Trial, Circulation, 133, 584, 10.1161/CIRCULATIONAHA.115.019657
Duncombe, 2017, Oscillometric and auscultatory blood pressure measurement methods in children: a systematic review and meta-analysis, J Hypertens, 35, 213, 10.1097/HJH.0000000000001178
Mingji, 2016, Assessing agreement of blood pressure-measuring devices in Tibetan areas of China: a systematic review, Heart Asia, 8, 46, 10.1136/heartasia-2016-010798
Wan, 2010, Determining which automatic digital blood pressure device performs adequately: a systematic review, J Hum Hypertens, 24, 431, 10.1038/jhh.2010.37
Cohen, 2019, History and justification of a national blood pressure measurement validated device listing, Hypertension, 73, 258, 10.1161/HYPERTENSIONAHA.118.11990
Ishikawa, 2012, Automatic office blood pressure measured without doctors or nurses present, Blood Press Monit, 17, 96, 10.1097/MBP.0b013e328352ade4
Stergiou, 2018, A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) collaboration statement, Hypertension, 71, 368, 10.1161/HYPERTENSIONAHA.117.10237
Roerecke, 2019, Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis, JAMA Intern Med, 179, 351, 10.1001/jamainternmed.2018.6551
Bauer, 2018, Attended versus unattended blood pressure measurement in a real life setting, Hypertension, 71, 243, 10.1161/HYPERTENSIONAHA.117.10026
Campbell, 2005, Automated assessment of blood pressure using BpTRU compared with assessments by a trained technician and a clinic nurse, Blood Press Monit, 10, 257, 10.1097/01.mbp.0000173486.44648.b2
Lamarre-Cliche, 2011, Comparative assessment of four blood pressure measurement methods in hypertensives, Can J Cardiol, 27, 455, 10.1016/j.cjca.2011.05.001
Myers, 2006, Automated blood pressure measurement in routine clinical practice, Blood Press Monit, 11, 59, 10.1097/01.mbp.0000200481.64787.c0
Myers, 2008, Comparison between an automated and manual sphygmomanometer in a population survey, Am J Hypertens, 21, 280, 10.1038/ajh.2007.54
Johnson, 2018, Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial), Hypertension, 71, 848, 10.1161/HYPERTENSIONAHA.117.10479
Stergiou, 2012, Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis, J Hypertens, 30, 2074, 10.1097/HJH.0b013e32835850d7
Chan, 2017, Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting, BMJ Open, 7, 10.1136/bmjopen-2016-013685
Cohen, 2019, Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis, Ann Intern Med, 170, 853, 10.7326/M19-0223
Pierdomenico, 2018, Prognostic value of masked uncontrolled hypertension, Hypertension, 72, 862, 10.1161/HYPERTENSIONAHA.118.11499
Shimbo, 2019, Should out-of-office monitoring be performed for detecting white coat hypertension?, Ann Intern Med, 170, 890, 10.7326/M19-1134
Ghazi, 2020, Association of 24-hour ambulatory blood pressure patterns with cognitive function and physical functioning in CKD, Clin J Am Soc Nephrol, 15, 455, 10.2215/CJN.10570919
Minutolo, 2007, Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial, Am J Kidney Dis, 50, 908, 10.1053/j.ajkd.2007.07.020
Mwasongwe, 2020, Ambulatory blood pressure phenotypes in adults taking antihypertensive medication with and without CKD, Clin J Am Soc Nephrol, 15, 501, 10.2215/CJN.08840719
Pogue, 2009, Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease, Hypertension, 53, 20, 10.1161/HYPERTENSIONAHA.108.115154
Siu, 2015, Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 163, 778, 10.7326/M15-2223
Little, 2002, Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care, BMJ, 325, 258, 10.1136/bmj.325.7358.258
McGowan, 2010, Self blood pressure monitoring: a worthy substitute for ambulatory blood pressure?, J Hum Hypertens, 24, 801, 10.1038/jhh.2010.15
Nasothimiou, 2014, Patients' preference for ambulatory versus home blood pressure monitoring, J Hum Hypertens, 28, 224, 10.1038/jhh.2013.104
Beyhaghi, 2019, Comparative cost-effectiveness of clinic, home, or ambulatory blood pressure measurement for hypertension diagnosis in US adults, Hypertension, 73, 121, 10.1161/HYPERTENSIONAHA.118.11715
Lovibond, 2011, Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study, Lancet, 378, 1219, 10.1016/S0140-6736(11)61184-7
Eguchi, 2012, A novel and simple protocol for the validation of home blood pressure monitors in clinical practice, Blood Press Monit, 17, 210, 10.1097/MBP.0b013e328356e196
Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee to Review the Dietary Reference Intakes for Sodium and Potassium, Oria M, Harrison M, Stallings VA, eds. Dietary Reference Intakes for Sodium and Potassium. Available at: http://doi.org/10.17226/25353. Accessed January 15, 2021.
Clase, 2020, Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, 97, 42, 10.1016/j.kint.2019.09.018
He, 2016, Urinary sodium and potassium excretion and CKD progression, J Am Soc Nephrol, 27, 1202, 10.1681/ASN.2015010022
Mills, 2016, Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease, JAMA, 315, 2200, 10.1001/jama.2016.4447
McMahon, 2015, Altered dietary salt intake for people with chronic kidney disease, Cochrane Database Syst Rev, 2, CD010070
Suckling, 2010, Altered dietary salt intake for preventing and treating diabetic kidney disease, Cochrane Database Syst Rev, CD006763
Hwang, 2014, Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial, Clin J Am Soc Nephrol, 9, 2059, 10.2215/CJN.01310214
Jardine, 2019, Dietary sodium reduction reduces albuminuria: a cluster randomized trial, J Ren Nutr, 29, 276
Keyzer, 2017, Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: the ViRTUE-CKD Trial, J Am Soc Nephrol, 28, 1296, 10.1681/ASN.2016040407
Konishi, 2001, Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy, Hypertension, 38, 81, 10.1161/01.HYP.38.1.81
Kwakernaak, 2014, Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial, Lancet Diabetes Endocrinol, 2, 385, 10.1016/S2213-8587(14)70030-0
McMahon, 2013, A randomized trial of dietary sodium restriction in CKD, J Am Soc Nephrol, 24, 2096, 10.1681/ASN.2013030285
Meuleman, 2017, Sodium restriction in patients with CKD: a randomized controlled trial of self-management support, Am J Kidney Dis, 69, 576, 10.1053/j.ajkd.2016.08.042
Ruilope, 1992, Sodium intake does not influence the effect of verapamil in hypertensive patients with mild renal insufficiency, Drugs, 44, 94, 10.2165/00003495-199200441-00017
Saran, 2017, A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD, Clin J Am Soc Nephrol, 12, 399, 10.2215/CJN.01120216
Slagman, 2011, Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial, BMJ, 343, d4366, 10.1136/bmj.d4366
Lopes de Faria, 1997, Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake, Nephron, 76, 411, 10.1159/000190223
Luik, 2002, Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus, Diabetologia, 45, 535, 10.1007/s00125-001-0763-8
Miller, 1997, Renal responses to sodium restriction in patients with early diabetes mellitus, J Am Soc Nephrol, 8, 749, 10.1681/ASN.V85749
Muhlhauser, 1996, Effects of dietary sodium on blood pressure in IDDM patients with nephropathy, Diabetologia, 39, 212, 10.1007/BF00403965
Trevisan, 1998, Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria, Diabetes, 47, 1347
Dodson, 1989, Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation, BMJ, 298, 227, 10.1136/bmj.298.6668.227
Houlihan, 2002, A low-sodium diet potentiates the effects of losartan in type 2 diabetes, Diabetes Care, 25, 663, 10.2337/diacare.25.4.663
Imanishi, 2001, Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients, Diabetes Care, 24, 111, 10.2337/diacare.24.1.111
Petrie, 1998, Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 83, 1552
Vedovato, 2004, Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance, Diabetologia, 47, 300, 10.1007/s00125-003-1303-5
Yoshioka, 1998, Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients, Diabetes Care, 21, 482, 10.2337/diacare.21.4.482
Lambers Heerspink, 2012, Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers, Kidney Int, 82, 330, 10.1038/ki.2012.74
2019, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, et al. Dietary reference values for sodium, EFSA J, 17, 191
Dunkler, 2013, Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus, JAMA Intern Med, 173, 1682
Smyth, 2014, The relationship between estimated sodium and potassium excretion and subsequent renal outcomes, Kidney Int, 86, 1205, 10.1038/ki.2014.214
Flesher, 2011, Self-management and biomedical outcomes of a cooking, and exercise program for patients with chronic kidney disease, J Ren Nutr, 21, 188
Greenwood, 2015, Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial, Am J Kidney Dis, 65, 425, 10.1053/j.ajkd.2014.07.015
Headley, 2014, Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial, Am J Kidney Dis, 64, 222, 10.1053/j.ajkd.2014.02.022
Howden, 2015, Exercise training in CKD: efficacy, adherence, and safety, Am J Kidney Dis, 65, 583, 10.1053/j.ajkd.2014.09.017
Ikizler, 2018, Metabolic effects of diet and exercise in patients with moderate to severe CKD: a randomized clinical trial, J Am Soc Nephrol, 29, 250, 10.1681/ASN.2017010020
Leehey, 2016, Structured exercise in obese diabetic patients with chronic kidney disease: a randomized controlled trial, Am J Nephrol, 44, 54, 10.1159/000447703
Leehey, 2009, Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study, Cardiovasc Diabetol, 8, 62, 10.1186/1475-2840-8-62
Van Craenenbroeck, 2015, Effect of moderate aerobic exercise training on endothelial function and arterial stiffness in CKD stages 3-4: a randomized controlled trial, Am J Kidney Dis, 66, 285, 10.1053/j.ajkd.2015.03.015
Heiwe, 2014, Exercise training in adults with CKD: a systematic review and meta-analysis, Am J Kidney Dis, 64, 383, 10.1053/j.ajkd.2014.03.020
Beddhu, 2015, Light-intensity physical activities and mortality in the United States general population and CKD subpopulation, Clin J Am Soc Nephrol, 10, 1145, 10.2215/CJN.08410814
Ekinci, 2011, Dietary salt intake and mortality in patients with type 2 diabetes, Diabetes Care, 34, 703, 10.2337/dc10-1723
Mente, 2018, Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study, Lancet, 392, 496, 10.1016/S0140-6736(18)31376-X
2020, Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial, BMC Med, 18, 91, 10.1186/s12916-020-01542-9
Mahajan, 2010, Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy, Kidney Int, 78, 303, 10.1038/ki.2010.129
Raphael, 2020, A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: the BASE Pilot Trial, J Am Soc Nephrol, 31, 161, 10.1681/ASN.2019030287
Graudal, 2017, Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride, Cochrane Database Syst Rev, 4, CD004022
Cheung, 2017, Effects of intensive BP control in CKD, J Am Soc Nephrol, 28, 2812, 10.1681/ASN.2017020148
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
Schrier, 2015, Blood pressure in early autosomal dominant polycystic kidney disease, N Engl J Med, 372, 976
Pajewski, 2020, Intensive vs standard blood pressure control in adults 80 years or older: a secondary analysis of the Systolic Blood Pressure Intervention Trial, J Am Geriatr Soc, 68, 496, 10.1111/jgs.16272
Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group, N Engl J Med, 330, 877, 10.1056/NEJM199403313301301
Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421
Ruggenenti, 2005, Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial, Lancet, 365, 939, 10.1016/S0140-6736(05)71082-5
Curb, 1996, Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group, JAMA, 276, 1886, 10.1001/jama.1996.03540230036032
Benavente, 2013, Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial, Lancet, 382, 507, 10.1016/S0140-6736(13)60852-1
Bundy, 2017, Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis, JAMA Cardiol, 2, 775, 10.1001/jamacardio.2017.1421
2014, Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5
Czernichow, 2011, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, J Hypertens, 29, 4, 10.1097/HJH.0b013e32834000be
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050
Williamson, 2019, Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial, JAMA, 321, 553, 10.1001/jama.2018.21442
Brunstrom, 2018, Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis, JAMA Intern Med, 178, 28, 10.1001/jamainternmed.2017.6015
Ninomiya, 2013, Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials, BMJ, 347, f5680, 10.1136/bmj.f5680
Malhotra, 2017, Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis, JAMA Intern Med, 177, 1498, 10.1001/jamainternmed.2017.4377
Garrison, 2017, Blood pressure targets for hypertension in older adults, Cochrane Database Syst Rev, 8, CD011575
Bavishi, 2017, Outcomes of intensive blood pressure lowering in older hypertensive patients, J Am Coll Cardiol, 69, 486, 10.1016/j.jacc.2016.10.077
1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 703, 10.1136/bmj.317.7160.703
Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6
Schrier, 2002, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes, Kidney Int, 61, 1086, 10.1046/j.1523-1755.2002.00213.x
Ruilope, 2001, Renal function and intensive lowering of blood pressure in hypertensive participant of the hypertension optimal treatment (HOT) study, J Am Soc Nephrol, 12, 218, 10.1681/ASN.V122218
Brunstrom, 2016, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses, BMJ, 352, i717, 10.1136/bmj.i717
Papademetriou, 2016, Cardiovascular outcomes in action to control cardiovascular risk in diabetes: impact of blood pressure level and presence of kidney disease, Am J Nephrol, 43, 271, 10.1159/000446122
Bress, 2017, Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial, Diabetes Care, 40, 1401, 10.2337/dc17-0885
Perkovic, 2015, Redefining Blood-Pressure Targets--SPRINT Starts the Marathon, N Engl J Med, 373, 2175, 10.1056/NEJMe1513301
Beddhu, 2018, Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT, J Am Heart Assoc, 7
Tsujimoto, 2018, Benefits of Intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control, Hypertension, 72, 323, 10.1161/HYPERTENSIONAHA.118.11408
Buckley, 2017, Intensive versus standard blood pressure control in SPRINT-Eligible participants of ACCORD-BP, Diabetes Care, 40, 1733, 10.2337/dc17-1366
Aggarwal, 2019, Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients, Hypertension, 73, 1275, 10.1161/HYPERTENSIONAHA.119.12697
Bangalore, 2010, J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial, Eur Heart J, 31, 2897, 10.1093/eurheartj/ehq328
D'Agostino, 1991, Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study, BMJ, 303, 385, 10.1136/bmj.303.6799.385
Beddhu, 2018, Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials, Lancet Diabetes Endocrinol, 6, 555, 10.1016/S2213-8587(18)30099-8
Beddhu, 2018, Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control, Circulation, 137, 134, 10.1161/CIRCULATIONAHA.117.030848
Kirchheim, 1987, Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs, Pflugers Arch, 410, 441, 10.1007/BF00586523
Malhotra, 2019, Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT, Am J Kidney Dis, 73, 21, 10.1053/j.ajkd.2018.07.015
Zhang, 2018, Kidney damage biomarkers and incident chronic kidney disease during blood pressure reduction: a case-control study, Ann Intern Med, 169, 610, 10.7326/M18-1037
Nadkarni, 2019, Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD Trial study participants, Am J Kidney Dis, 73, 31, 10.1053/j.ajkd.2018.07.016
Beddhu, 2017, Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial, Ann Intern Med, 167, 375, 10.7326/M16-2966
Appel, 2010, Intensive blood-pressure control in hypertensive chronic kidney disease, N Engl J Med, 363, 918, 10.1056/NEJMoa0910975
Beck, 1991, Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group, Control Clin Trials, 12, 566, 10.1016/0197-2456(91)90069-X
Upadhyay, 2011, Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier, Ann Intern Med, 154, 541, 10.7326/0003-4819-154-8-201104190-00335
Sarnak, 2005, The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study, Ann Intern Med, 142, 342, 10.7326/0003-4819-142-5-200503010-00009
1996, Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study, J Am Soc Nephrol, 7, 2097, 10.1681/ASN.V7102097
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
2012, KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease, Kidney Int Suppl, 2, 337
Wuhl, 2009, Strict blood-pressure control and progression of renal failure in children, N Engl J Med, 361, 1639, 10.1056/NEJMoa0902066
Pahor, 1998, Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program, Arch Intern Med, 158, 1340, 10.1001/archinte.158.12.1340
Ku, 2017, BP Control and long-term risk of ESRD and mortality, J Am Soc Nephrol, 28, 671, 10.1681/ASN.2016030326
Ku, 2015, Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease, Kidney Int, 87, 1055, 10.1038/ki.2014.376
Chan, 2009, Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study, Diabetes Care, 32, 977, 10.2337/dc08-1908
Estacio, 2006, Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes, Am J Hypertens, 19, 1241, 10.1016/j.amjhyper.2006.05.011
Lewis, 1999, Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group, Am J Kidney Dis, 34, 809, 10.1016/S0272-6386(99)70036-3
Juraschek, 2020, Orthostatic Hypotension, cardiovascular outcomes, and adverse events: results from SPRINT, Hypertension, 75, 660, 10.1161/HYPERTENSIONAHA.119.14309
Rocco, 2018, Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT), Am J Kidney Dis, 71, 352, 10.1053/j.ajkd.2017.08.021
Obi, 2018, Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial, J Intern Med, 283, 314, 10.1111/joim.12701
Nguyen, 2018, Effect of additional antihypertensive medications in patients with high-risk hypertension: a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) database, J Clin Hypertens (Greenwich), 20, 814, 10.1111/jch.13258
Markovitz, 2017, Incremental effects of antihypertensive drugs: instrumental variable analysis, BMJ, 359, j5542, 10.1136/bmj.j5542
Bress, 2017, Cost-effectiveness of intensive versus standard blood-pressure control, N Engl J Med, 377, 745, 10.1056/NEJMsa1616035
Wang, 2005, Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease, Am J Kidney Dis, 45, 494, 10.1053/j.ajkd.2004.11.011
Zhang, 2007, Association between carotid artery intima-media thickness and early-stage CKD in a Chinese population, Am J Kidney Dis, 49, 786, 10.1053/j.ajkd.2007.03.011
Nerenberg, 2018, Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children, Can J Cardiol, 34, 506, 10.1016/j.cjca.2018.02.022
Hiremath, 2020, Hypertension Canada's 2020 evidence review and guidelines for the management of resistant hypertension, Can J Cardiol, 36, 625, 10.1016/j.cjca.2020.02.083
Muntner, 2019, Rationale for ambulatory and home blood pressure monitoring thresholds in the 2017 American College of Cardiology/American Heart Association Guideline, Hypertension, 73, 33, 10.1161/HYPERTENSIONAHA.118.11946
Rahman, 2005, Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 165, 936, 10.1001/archinte.165.8.936
Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303
2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7
2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9
Solomon, 2006, Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial, Circulation, 114, 26, 10.1161/CIRCULATIONAHA.105.592733
Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007
Mann, 2001, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial, Ann Intern Med, 134, 629, 10.7326/0003-4819-134-8-200104170-00007
Dagenais, 2006, Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials, Lancet, 368, 581, 10.1016/S0140-6736(06)69201-5
Xie, 2016, Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials, Am J Kidney Dis, 67, 728, 10.1053/j.ajkd.2015.10.011
Gashti, 2004, The role of calcium antagonists in chronic kidney disease, Curr Opin Nephrol Hypertens, 13, 115, 10.1097/00041552-200403000-00003
Williams, 2015, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial, Lancet, 386, 2059, 10.1016/S0140-6736(15)00257-3
Hripcsak, 2020, Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension, JAMA Intern Med, 180, 542, 10.1001/jamainternmed.2019.7454
Lederle, 2016, Chlorthalidone versus hydrochlorothiazide: a new kind of veterans affairs cooperative study, Ann Intern Med, 165, 663, 10.7326/M16-1208
Moran, 2020, Chlorthalidone and hydrochlorothiazide for treatment of patients with hypertension, JAMA Intern Med, 180, 1132, 10.1001/jamainternmed.2020.1739
Jentzer, 2010, Combination of loop diuretics with thiazide-type diuretics in heart failure, J Am Coll Cardiol, 56, 1527, 10.1016/j.jacc.2010.06.034
1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8
Ruggenenti, 1999, Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria, Lancet, 354, 359, 10.1016/S0140-6736(98)10363-X
Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502
Hou, 2006, Efficacy and safety of benazepril for advanced chronic renal insufficiency, N Engl J Med, 354, 131, 10.1056/NEJMoa053107
Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis, Ann Intern Med, 139, 244, 10.7326/0003-4819-139-4-200308190-00006
Hou, 2007, Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency, J Am Soc Nephrol, 18, 1889, 10.1681/ASN.2006121372
Hannedouche, 1994, Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure, BMJ, 309, 833, 10.1136/bmj.309.6958.833
Rakugi, 2013, Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial, Hypertens Res, 36, 947, 10.1038/hr.2013.63
Esnault, 2008, The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study, Clin Ther, 30, 482, 10.1016/j.clinthera.2008.03.006
Marin, 1995, Effect of antihypertensive treatment on progression of renal insufficiency in non-diabetics patients (ESPIRAL Trial), Nefrologia, 15, 464
Zucchelli, 1992, Long-term comparison between captopril and nifedipine in the progression of renal insufficiency, Kidney Int, 42, 452, 10.1038/ki.1992.309
Woo, 2014, Aliskiren and losartan trial in non-diabetic chronic kidney disease, J Renin Angiotensin Aldosterone Syst, 15, 515, 10.1177/1470320313510584
Mimura, 2008, Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases, J Hum Hypertens, 22, 38, 10.1038/sj.jhh.1002264
Ihle, 1996, Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial, Am J Kidney Dis, 27, 489, 10.1016/S0272-6386(96)90158-4
Cinotti, 2001, Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies, Nephrol Dial Transplant, 16, 961, 10.1093/ndt/16.5.961
Shen, 2012, Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease, J Investig Med, 60, 1041, 10.2310/JIM.0b013e31826741d2
Nakamura, 2005, An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency, Hypertens Res, 28, 415, 10.1291/hypres.28.415
Ando, 2014, Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol, 2, 944, 10.1016/S2213-8587(14)70194-9
Chung, 2020, Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease, Cochrane Database of Syst Rev, 10, CD007004
Edwards, 2009, Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial, J Am Coll Cardiol, 54, 505, 10.1016/j.jacc.2009.03.066
Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492
Herzog, 2011, Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 80, 572, 10.1038/ki.2011.223
Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301
Mann, 2009, Effect of telmisartan on renal outcomes: a randomized trial, Ann Intern Med, 151, 1, 10.7326/0003-4819-151-1-200907070-00122
Wright, 2005, Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril, JAMA, 293, 1595, 10.1001/jama.293.13.1595
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Gerstein, 2000, Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators, Diabetes Care, 23, B35
Mann, 2003, Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study, Am J Kidney Dis, 42, 936, 10.1016/j.ajkd.2003.07.015
Maschio, 1999, Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group, J Cardiovasc Pharmacol, S16, 10.1097/00005344-199900001-00004
Bakris, 1992, Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection, Kidney Int, 41, 912, 10.1038/ki.1992.139
Bakris, 1994, ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects, J Diabetes Complications, 8, 2, 10.1016/1056-8727(94)90003-5
Bojestig, 2001, Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes, Diabetes Care, 24, 919, 10.2337/diacare.24.5.919
Capek, 1994, Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study, Clin Investig, 72, 961, 10.1007/BF00577736
Chase, 1993, Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial, Ann Ophthalmol, 25, 284
Cordonnier, 1999, Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group, J Am Soc Nephrol, 10, 1253, 10.1681/ASN.V1061253
Crepaldi, 1998, Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM, Diabetes Care, 21, 104, 10.2337/diacare.21.1.104
Garg, 1998, Renal and retinal changes after treatment with ramipril and pentoxifyline in subjects with IDDM, Ann Ophthalmol Glaucoma, 30, 33
Hommel, 1995, Long-term effect of captopril on kidney function in normotensive insulin dependent diabetic patients (iddm) with diabetic nephropathy [abstract], J Am Soc Nephrol, 6, 450
Katayama, 2002, Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM), Diabetes Res Clin Pract, 55, 113, 10.1016/S0168-8227(01)00289-3
Laffel, 1995, The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group, Am J Med, 99, 497, 10.1016/S0002-9343(99)80226-5
Marre, 2004, Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study), BMJ, 328, 495, 10.1136/bmj.37970.629537.0D
Mathiesen, 1991, Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria, BMJ, 303, 81, 10.1136/bmj.303.6794.81
Mauer, 2009, Renal and retinal effects of enalapril and losartan in type 1 diabetes, N Engl J Med, 361, 40, 10.1056/NEJMoa0808400
Nankervis, 1998, Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study, Metabolism, 47, 12, 10.1016/S0026-0495(98)90364-X
Parving, 1989, Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy, BMJ, 299, 533, 10.1136/bmj.299.6698.533
Phillips, 1993, Diabetic microalbuminuria and cilazapril, Am J Med, 94, 58s
Ravid, 1993, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients, Ann Intern Med, 118, 577, 10.7326/0003-4819-118-8-199304150-00001
Romero, 1993, Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors, Diabetes Care, 16, 597, 10.2337/diacare.16.4.597
Sano, 1994, Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients, Diabetes Care, 17, 420, 10.2337/diacare.17.5.420
Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004
1997, Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria, Lancet, 349, 1787, 10.1016/S0140-6736(96)10244-0
Ahmad, 2003, Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects, Diabetes Res Clin Pract, 60, 131, 10.1016/S0168-8227(03)00016-0
Ahmad, 1997, Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria, Diabetes Care, 20, 1576, 10.2337/diacare.20.10.1576
Hansen, 1994, Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients, Diabete Metab, 20, 485
Jerums, 2004, Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria, Diabet Med, 21, 1192, 10.1111/j.1464-5491.2004.01316.x
Jerums, 2001, Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria, Am J Kidney Dis, 37, 890, 10.1016/S0272-6386(05)80003-4
Muirhead, 1999, The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial, Curr Therapeutic Res, 60, 650, 10.1016/S0011-393X(99)90003-6
O'Hare, 2000, Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial, Diabetes Care, 23, 1823, 10.2337/diacare.23.12.1823
Winocour, 1987, Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria, Br Med J (Clin Res Ed), 295, 391, 10.1136/bmj.295.6594.391
Imai, 2011, Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study, Diabetologia, 54, 2978, 10.1007/s00125-011-2325-z
Mehdi, 2009, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, J Am Soc Nephrol, 20, 2641, 10.1681/ASN.2009070737
Barnett, 2004, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy, N Engl J Med, 351, 1952, 10.1056/NEJMoa042274
Ko, 2005, Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril, Adv Ther, 22, 155, 10.1007/BF02849886
Rizzoni, 2005, Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus, Hypertension, 45, 659, 10.1161/01.HYP.0000153308.91043.97
Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081
van den Meiracker, 2006, Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function, J Hypertens, 24, 2285, 10.1097/01.hjh.0000249708.44016.5c
Bjorck, 1992, Renal protective effect of enalapril in diabetic nephropathy, BMJ, 304, 339, 10.1136/bmj.304.6823.339
De Cesaris, 1993, Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients, J Cardiovasc Pharmacol, 22, 208, 10.1097/00005344-199308000-00006
Elving, 1994, Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study, Diabetologia, 37, 604, 10.1007/BF00403380
Nielsen, 1994, Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy, Diabetes, 43, 1108, 10.2337/diab.43.9.1108
Nielsen, 1997, Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy, Diabetes, 46, 1182, 10.2337/diab.46.7.1182
Rudberg, 1999, Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus, Diabetologia, 42, 589, 10.1007/s001250051199
Schnack, 1996, Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria, Diabetologia, 39, 1611, 10.1007/s001250050623
Stornello, 1992, Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers, Clin Sci (Lond), 82, 19, 10.1042/cs0820019
Guasch, 1997, Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy, J Am Soc Nephrol, 8, 793, 10.1681/ASN.V85793
Holdaas, 1991, Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy, J Intern Med, 229, 163, 10.1111/j.1365-2796.1991.tb00325.x
Karalliedde, 2008, Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering, Hypertension, 51, 1617, 10.1161/HYPERTENSIONAHA.108.111674
Norgaard, 1993, A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension, Blood Press, 2, 301, 10.3109/08037059309077172
O'Donnell, 1993, Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study, J Hum Hypertens, 7, 333
Tarnow, 1999, Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy, Diabetes Care, 22, 491, 10.2337/diacare.22.3.491
Thomas, 2005, Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes, Kidney Int, 67, 2494, 10.1111/j.1523-1755.2005.00359.x
2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet, 370, 829, 10.1016/S0140-6736(07)61303-8
Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med, 383, 2219, 10.1056/NEJMoa2025845
Strippoli, 2006, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease, Cochrane Database Syst Rev, 4, CD006257
Balshem, 2011, GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 64, 401, 10.1016/j.jclinepi.2010.07.015
Cheng, 2014, Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis, JAMA Intern Med, 174, 773, 10.1001/jamainternmed.2014.348
Bangalore, 2016, Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials, BMJ, 352, i438, 10.1136/bmj.i438
Clase, 2017, Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes, Kidney Int, 91, 683, 10.1016/j.kint.2016.09.038
Bandak, 2017, Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project, J Am Heart Assoc, 6
Jun, 2019, Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study, PLoS One, 14, 10.1371/journal.pone.0213192
Spinowitz, 2019, Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study, Clin J Am Soc Nephrol, 14, 798, 10.2215/CJN.12651018
Weir, 2015, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors, N Engl J Med, 372, 211, 10.1056/NEJMoa1410853
Collard, 2018, Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus, Hypertension, 72, 1337, 10.1161/HYPERTENSIONAHA.118.11944
Ku, 2018, Acute declines in renal function during intensive BP lowering and long-term risk of death, J Am Soc Nephrol, 29, 2401, 10.1681/ASN.2018040365
Schmidt, 2017, Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study, BMJ, 356, j791, 10.1136/bmj.j791
Qiao, 2020, Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate, JAMA Intern Med, 180, 718, 10.1001/jamainternmed.2020.0193
Ahmed, 2010, The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease, Nephrol Dial Transplant, 25, 3977, 10.1093/ndt/gfp511
Oxlund, 2013, Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial, J Hypertens, 31, 2094, 10.1097/HJH.0b013e3283638b1a
Dhaybi, 2017, Mineralocorticoid antagonists in chronic kidney disease, Curr Opin Nephrol Hypertens, 26, 50, 10.1097/MNH.0000000000000290
Bakris, 2019, Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial, Am J Nephrol, 50, 333, 10.1159/000503713
Agarwal, 2019, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 394, 1540, 10.1016/S0140-6736(19)32135-X
Menne, 2008, Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial, J Hypertens, 26, 1860, 10.1097/HJH.0b013e32830508aa
Tobe, 2011, Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies, Circulation, 123, 1098, 10.1161/CIRCULATIONAHA.110.964171
Fernandez Juarez, 2013, Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial, Am J Kidney Dis, 61, 211, 10.1053/j.ajkd.2012.07.011
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Sharma, 2011, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease, Cochrane Database Syst Rev, 10, CD007751
Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928
Ferrari, 2002, Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade, J Hypertens, 20, 125, 10.1097/00004872-200201000-00018
Leon, 2019, The use of renin-angiotensin system inhibitors in patients with chronic kidney disease, Can J Cardiol, 35, 1220, 10.1016/j.cjca.2019.06.029
Anand, 2013, Direct renin inhibitors for preventing the progression of diabetic kidney disease, Cochrane Database Syst Rev, 9, CD01072
Bakris, 2013, Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus, J Clin Hypertens (Greenwich), 15, 92, 10.1111/jch.12032
Fogari, 2013, Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria, Expert Opin Pharmacother, 14, 371, 10.1517/14656566.2013.772981
Ohsawa, 2013, Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease, Int J Mol Sci, 14, 15361, 10.3390/ijms140815361
Parving, 2012, Cardiorenal end points in a trial of aliskiren for type 2 diabetes, N Engl J Med, 367, 2204, 10.1056/NEJMoa1208799
Parving, 2008, Aliskiren combined with losartan in type 2 diabetes and nephropathy, N Engl J Med, 358, 2433, 10.1056/NEJMoa0708379
Persson, 2010, Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial, Diabetologia, 53, 1576, 10.1007/s00125-010-1789-6
Burgess, 2009, Supramaximal dose of candesartan in proteinuric renal disease, J Am Soc Nephrol, 20, 893, 10.1681/ASN.2008040416
Ruggenenti, 2008, Role of remission clinics in the longitudinal treatment of CKD, J Am Soc Nephrol, 19, 1213, 10.1681/ASN.2007090970
Ruggenenti, 2008, Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies, Clin J Am Soc Nephrol, 3, 1511, 10.2215/CJN.04140907
Currie, 2016, Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis, BMC Nephrol, 17, 127, 10.1186/s12882-016-0337-0
Cross, 2009, Antihypertensive treatment for kidney transplant recipients, Cochrane Database Syst Rev, 3, CD003598
2009, KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant, 9, S1
Seeman, 2013, ESCORT trial-effects of strict control of blood pressure in pediatric renal transplant recipients-baseline characteristics of patients from a randomized controlled trial [abstract no: P-SAT456], Pediatric Nephrology, 28, 1531
Carpenter, 2014, BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial, J Am Soc Nephrol, 25, 1554, 10.1681/ASN.2013040435
Opelz, 1998, Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study, Kidney Int, 53, 217, 10.1046/j.1523-1755.1998.00744.x
Pagonas, 2019, Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation, Sci Rep, 9, 10507, 10.1038/s41598-019-46991-2
Beddhu, 2019, Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT, J Am Soc Nephrol, 30, 1523, 10.1681/ASN.2018121261
Fernandez Fresnedo, 2012, Ambulatory blood pressure monitoring in kidney transplant patients: RETENAL study, Transplant Proc, 44, 2601, 10.1016/j.transproceed.2012.09.037
Mallamaci, 2019, Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study, Nephrol Dial Transplant, 34, 1558, 10.1093/ndt/gfy355
Tong, 2017, Toward establishing core outcome domains for trials in kidney transplantation: report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops, Transplantation, 101, 1887, 10.1097/TP.0000000000001774
Tong, 2018, Establishing a core outcome measure for graft health: a Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop report, Transplantation, 102, 1358, 10.1097/TP.0000000000002125
Alcaraz, 1991, Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels, Transplant Proc, 23, 2383
Campistol, 1991, Interaction between ciclosporin and diltiazem in renal transplant patients, Nephron, 57, 241, 10.1159/000186262
Chen, 2013, Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study, Clin Transplant, 27, E272, 10.1111/ctr.12101
Chrysostomou, 1993, Diltiazem in renal allograft recipients receiving cyclosporine, Transplantation, 55, 300, 10.1097/00007890-199302000-00014
Dawidson, 1991, Verapamil improves the outcome after cadaver renal transplantation, J Am Soc Nephrol, 2, 983, 10.1681/ASN.V25983
Frei, 1990, Calcium channel blockers for kidney protection, J Cardiovasc Pharmacol, 16, S11, 10.1097/00005344-199006166-00004
Guerin, 1989, Effects of diltiazem on arterial pressure and renal function in renal transplanted and cyclosporin A treated subjects. Results after 3 months of a prospective study, Arch Mal Coeur Vaiss, 82, 1223
Harper, 1996, The beneficial effects of oral nifedipine on cyclosporin-treated renal transplant recipients--a randomised prospective study, Transplant Int, 9, 115, 10.1111/j.1432-2277.1996.tb00865.x
Ladefoged, 1994, Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study, Nephrol Dial Transplant, 9, 543, 10.1093/ndt/9.5.543
Lehtonen, 2000, A randomised placebo controlled study on initial isradipine therapy in renal transplantation: long-term results [abstract], Nephrol Dial Transplant, 15, A276
Morales, 1989, Calcium antagonist treatment of recipients minimizes early cyclosporine nephrotoxicity in renal transplantation: a prospective randomized trial, Transplant Proc, 21, 1537
Morales, 1994, Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study, Transplant Proc, 26, 2598
Patton, 1994, A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome, Transplantation, 57, 889, 10.1097/00007890-199403270-00021
Pirsch, 1993, A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients, Am J Kidney Dis, 21, 189, 10.1016/S0272-6386(12)81092-4
Rahn, 1999, Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial, Lancet, 354, 1415, 10.1016/S0140-6736(99)08421-4
Van den Dorpel, 1994, Prophylactic isradipine treatment after kidney transplantation: a prospective double-blind placebo-controlled randomized trial, Transplant Int, 7, S270, 10.1111/j.1432-2277.1994.tb01365.x
van Riemsdijk, 2000, Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study, Transplantation, 70, 122
Wagner, 1986, Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study, Dtsch Med Wochenschr, 111, 1363, 10.1055/s-2008-1068635
Wahlberg, 1992, Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients, Transplant Proc, 24, 311
Wilkie, 1994, A double-blind, randomized, placebo-controlled study of nifedipine on early renal allograft function, Nephrol Dial Transplant, 9, 800
Ibrahim, 2013, Angiotensin II blockade in kidney transplant recipients, J Am Soc Nephrol, 24, 320, 10.1681/ASN.2012080777
Philipp, 2010, Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET, Nephrol Dial Transplant, 25, 967, 10.1093/ndt/gfp581
Salzberg, 2014, Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade, Am J Nephrol, 39, 1, 10.1159/000357205
Kuypers, 2004, Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study, Transplantation, 78, 1204, 10.1097/01.TP.0000137793.23371.42
Sperschneider, 1997, Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients, Med Klin (Munich), 92, 589, 10.1007/BF03044784
van der Schaaf, 1995, Hypertension after renal transplantation. Calcium channel or converting enzyme blockade?, Hypertension, 25, 77, 10.1161/01.HYP.25.1.77
Venkat Raman, 1999, Renal effects of amlodipine in normotensive renal transplant recipients, Nephrol Dial Transplant, 14, 384, 10.1093/ndt/14.2.384
Wilkie, 1993, Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients, Transplant Proc, 25, 612
Makani, 2011, Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials, J Hypertens, 29, 1270, 10.1097/HJH.0b013e3283472643
Schmidt, 2017, Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study, BMJ Open, 7, 10.1136/bmjopen-2016-012818
Amara, 2010, Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy, Transplantation, 89, 104, 10.1097/TP.0b013e3181bf13d9
Beckingham, 1995, A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation, Nephrol Dial Transplantat, 10, 2316, 10.1093/ndt/10.12.2316
Glicklich, 2011, Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double-blinded placebo-controlled safety study, Clin Transplant, 25, 843, 10.1111/j.1399-0012.2010.01372.x
Gronhagen-Riska, 1984, Angiotensin I-converting enzyme inhibition after renal transplantation, Scand J Urol Nephrol Suppl, 79, 63, 10.1080/00365599.1984.11783718
Hernandez, 1995, Usefulness and safety of treatment with captopril in posttransplant erythrocytosis, Transplantation Proc, 27, 2239
Kim, 2002, The effect of enalapril on the progression of chronic allograft nephropathy. [abstract], Nephrol Dial Transplant, 17, 324
Knoll, 2016, Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial, Lancet Diabetes Endocrinol, 4, 318, 10.1016/S2213-8587(15)00368-X
Mandelbrot, 2015, Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus, Am J Transplant, 15, 3174, 10.1111/ajt.13384
Paoletti, 2007, ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial, Am J Kidney Dis, 50, 133, 10.1053/j.ajkd.2007.04.013
Rashtchizadeh, 2007, Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms, Clin Biochem, 40, 194, 10.1016/j.clinbiochem.2006.10.023
Takahara, 2002, Randomized prospective study of effects of benazepril in renal transplantation: an analysis of safety and efficacy, Clin Exper Nephrol, 6, 242, 10.1007/s101570200041
Trivedi, 2003, A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis, Ren Fail, 25, 77, 10.1081/JDI-120017470
Zhang, 2008, Treatment of chronic allograft nephropathy with combination of enalapril and bailing capsule, Zhongguo Zhong Xi Yi Jie He Za Zhi, 28, 806
Vanrenterghem, 1988, Controlled trial of the protective effect of dihydroergotoxine (Hydergine) on cyclosporine-associated nephrotoxicity in renal graft recipients, Transplantation Proc, 20, 615
Tylicki, 2006, Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients, Transplantation, 81, 52, 10.1097/01.tp.0000188137.50178.7d
Medeiros, 2017, Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy, Clin J Am Soc Nephrol, 12, 1291, 10.2215/CJN.05300516
Axelrod, 2018, An economic assessment of contemporary kidney transplant practice, Am J Transplant, 18, 1168, 10.1111/ajt.14702
Chung, 2014, Economic evaluations in kidney transplantation: frequency, characteristics, and quality-a systematic review, Transplantation, 97, 1027, 10.1097/TP.0000000000000079
Wuhl, 2002, Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions, J Hypertens, 21, 1995, 10.1097/00004872-200210000-00019
Lurbe, 2016, 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents, J Hypertens, 34, 1887, 10.1097/HJH.0000000000001039
Simonetti, 2007, Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management, Paediatr Drugs, 9, 413, 10.2165/00148581-200709060-00008
Matteucci, 2013, Change in cardiac geometry and function in CKD children during strict BP control: a randomized study, Clin J Am Soc Nephrol, 8, 203, 10.2215/CJN.08420811
Flynn, 2014, Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association, Hypertension, 63, 1116, 10.1161/HYP.0000000000000007
Ku, 2018, Twenty-four-hour ambulatory blood pressure versus clinic blood pressure measurements and risk of adverse outcomes in children with CKD, Clin J Am Soc Nephrol, 13, 422, 10.2215/CJN.09630917
Stergiou, 2011, Comparison of office, ambulatory and home blood pressure in children and adolescents on the basis of normalcy tables, J Hum Hypertens, 25, 218, 10.1038/jhh.2010.59
Stergiou, 2017, Accuracy of automated blood pressure measurement in children: evidence, issues, and perspectives, Hypertension, 69, 1000, 10.1161/HYPERTENSIONAHA.116.08553
Wuhl, 2004, Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure, Pediatr Res, 55, 492, 10.1203/01.PDR.0000106863.90996.76
Warady, 2015, Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort, Am J Kidney Dis, 65, 878, 10.1053/j.ajkd.2015.01.008
Stergiou, 2019, Home blood pressure monitoring in children and adolescents: systematic review of evidence on clinical utility, Curr Hypertens Rep, 21, 64, 10.1007/s11906-019-0967-2
Dionne, 2017, Ambulatory blood pressure and CKD progression in the CKiD cohort [Abstract FR-PO543], J Am Soc Nephrol, 28, 542
Hanson, 2019, Identifying important outcomes for young people with CKD and their caregivers: a nominal group technique study, Am J Kidney Dis, 74, 82, 10.1053/j.ajkd.2018.12.040
Halbach, 2020, Practical application of ABPM in the pediatric nephrology clinic, Pediatr Nephrol, 35, 2067, 10.1007/s00467-019-04361-0
Flynn JT, Carroll MK, Ng DK, et al. Achieved clinic blood pressure level and chronic kidney disease progression in children: a report from the Chronic Kidney Disease in Children Cohort [e-pub ahead of print]. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04833-8. Accessed January 15, 2021.
Kogon, 2014, Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease, Kidney Int, 85, 938, 10.1038/ki.2013.352
Flynn, 2008, Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study, Hypertension, 52, 631, 10.1161/HYPERTENSIONAHA.108.110635
Hari, 2013, Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial, Indian Pediatr, 50, 923, 10.1007/s13312-013-0262-2
Seeman, 2007, Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy, Am J Hypertens, 20, 990, 10.1016/j.amjhyper.2007.03.009
Cheung, 2019, Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, 95, 1027, 10.1016/j.kint.2018.12.025
2011
Schunemann, 2006, Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations, Health Res Policy Syst, 4, 21, 10.1186/1478-4505-4-21
Brouwers, 2010, AGREE II: advancing guideline development, reporting and evaluation in health care, J Clin Epidemiol, 63, 1308, 10.1016/j.jclinepi.2010.07.001
Hahn, 2020, Low protein diets for non-diabetic adults with chronic kidney disease, Cochrane Database Syst Rev, 10, CD001892
Palmer, 2017, Dietary interventions for adults with chronic kidney disease, Cochrane Database Syst Rev, 4, CD011998
Heiwe, 2011, Exercise training for adults with chronic kidney disease (Review), Cochrane Database of Syst Rev, 10, CD00323
Natale, 2020, Potassium binders for chronic hyperkalaemia in people with chronic kidney disease, Cochrane Database Syst Rev, 6, CD013165
Bagga, 2014, Antihypertensive agents for children with chronic kidney disease (Protocol), Cochrane Database of Systematic Reviews, 1, CD010911
2019
Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011
Shea, 2017, AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both, BMJ, 358, j4008, 10.1136/bmj.j4008
Whiting, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009
Guyatt, 2011, GRADE guidelines 6. Rating the quality of evidence--imprecision, J Clin Epidemiol, 64, 1283, 10.1016/j.jclinepi.2011.01.012